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Abstract
Autism spectrum disorder (ASD) is characterized by a complex polygenic back-
ground, but with the unique feature of a subset of cases (~15%-30%) presenting a 
rare large-effect variant. However, clinical interpretation in these cases is often com-
plicated by incomplete penetrance, variable expressivity and different neurodevel-
opmental trajectories. NRXN1 intragenic deletions represent the prototype of such 
ASD-associated susceptibility variants. From chromosomal microarrays analysis of 
104 ASD individuals, we identified an inherited NRXN1 deletion in a trio family. We 
carried out whole-exome sequencing and deep sequencing of mitochondrial DNA 
(mtDNA) in this family, to evaluate the burden of rare variants which may contribute 
to the phenotypic outcome in NRXN1 deletion carriers. We identified an increased 
burden of exonic rare variants in the ASD child compared to the unaffected NRXN1 
deletion-transmitting mother, which remains significant if we restrict the analysis to 
potentially deleterious rare variants only (P = 6.07 × 10−5). We also detected sig-
nificant interaction enrichment among genes with damaging variants in the proband, 
suggesting that additional rare variants in interacting genes collectively contribute 
to cross the liability threshold for ASD. Finally, the proband's mtDNA presented five 
low-level heteroplasmic mtDNA variants that were absent in the mother, and two 
maternally inherited variants with increased heteroplasmic load. This study under-
lines the importance of a comprehensive assessment of the genomic background in 
carriers of large-effect variants, as penetrance modulation by additional interacting 
rare variants to might represent a widespread mechanism in neurodevelopmental 
disorders.
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1  | INTRODUC TION
Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelop-
mental disorder with a high prevalence (>1%) and a remarkable social 
burden, with no effective pharmacological treatments.1 Despite the 
high heritability, the vast majority of genetic risk factors still remains 
unknown and only about 15%-30% of ASD individuals have an iden-
tifiable genetic cause.2
Several years of investigation has led to considerable progress 
in the identification of a large number of risk genes and the delin-
eation of a heterogeneous and complex genetic architecture. It is 
now evident that ASD, like other neuropsychiatric disorders, has 
a polygenic basis, but with the peculiarity of a subset of cases 
where a large-effect variant is present. Advance in microarrays and 
whole-exome sequencing (WES) enabled the discovery of many 
rare variants of large effect, both structural and single-nucleotide 
variants, which pinpointed more than 100 high-confidence specific 
genes and genetic loci.3-5 Even if the identification of rare genic likely 
pathogenic mutations can be extremely informative, their transla-
tion into clinical settings is not straightforward, as many of them are 
characterized by incomplete penetrance and variable expressivity. 
It is possible that these rare large-effect variants may act affecting 
neurodevelopmental processes common to different disorders and 
the final clinical manifestation rely on the presence of additional risk 
variants that allow crossing the threshold for clear neuropsychiatric 
disorders, ultimately defining the specific phenotypic trajectory in 
the carrier. There are several examples where the penetrance of a 
‘pathogenic’ copy number variants (CNV) is increased by the pres-
ence of additional risk CNVs.6
Rare intragenic deletions affecting Neurexin-1 (NRXN1) repre-
sent the prototype example of susceptibility variants for neurodevel-
opmental disorders with such complexity.7,8 NRXN1 belongs to the 
neurexin family encoding for an evolutionarily conserved presynap-
tic cell adhesion molecules involved in formation and maintenance of 
synaptic connections and vesicular neurotransmitter release. NRXN1 
is transcribed in neurons from two independent promoters which 
generate a longer alpha (α) and a shorter beta (β) isoform, composed 
of distinct extracellular domains but with an identical intracellular se-
quence. Moreover, through extensive alternative splicing, thousands 
of isoforms are produced and differentially expressed throughout 
the brain, with a likely role as surface recognition molecules that 
specify synapses.9 The NRXN1 locus is extremely prone to non-re-
current deletions with different size and breakpoint location, result-
ing from chromosomal rearrangements due to genomic instability. 
Rare intragenic deletions spanning NRXN1 have been described in 
individuals with ASD, Attention-Deficit/Hyperactivity Disorder 
(ADHD), intellectual disability (ID), epilepsy, schizophrenia and bipo-
lar disorder, but also in unaffected parents, siblings and healthy con-
trols, suggesting reduced penetrance and the contribution of other 
interacting genetic and/or environmental factors that influence clin-
ical features and severity.7,8 The enhanced frequency of additional 
pathogenic CNVs in cohorts of patients carrying NRXN1 deletions 
has added support to the role of secondary and independently seg-
regating genetic risk factors in the definition of the final phenotype 
in children with inherited deletions. Previous studies suggested that 
deletion extent and exon content may also play a role in this clinical 
heterogeneity; however, there is no consensus on the different pen-
etrance of 5′ NRXN1 deletions (exons 1-6, NM_001135659.2) versus 
3′ NRXN1 deletions (exons 7-24, NM_001135659.2). Specifically, 
one study proposed a lower penetrance of 3′ NRXN1 deletions as 
they are more frequently co-occurring with another rare and often 
pathogenic CNV,7 while a more recent study reported a higher pen-
etrance of 3′ deletions, given the much higher frequencies in cases 
versus controls and the higher de novo occurrence.8
In order to identify pathogenic CNVs in ASD probands, we per-
formed array-based comparative genomic hybridization (aCGH) on a 
cohort of 104 ASD individuals from 89 Italian families. A 3′ NRXN1 
deletion was identified in a trio family in which a girl with ASD in-
herited the deletion from the unaffected mother. To further explore 
the impact of genetic background on the penetrance of NRXN1 de-
letions, a detailed clinical evaluation of the girl and her parents was 
combined with genetic analysis including (a) WES, in order to charac-
terize the background of rare variants and (b) deep sequencing of the 
entire mitochondrial genome, with the aim of detecting rare patho-
genic mutations and evaluating the burden of low-heteroplasmy 
variants. Mitochondrial DNA (mtDNA) defects could, indeed, rep-
resent an overlooked contributing factor to ASD susceptibility, by 
reducing mitochondrial function sufficiently to fall below the brain's 
bioenergetics threshold.10 Moreover, a recent study has provided 
evidence for a coordinated down-regulation of synaptic and mito-
chondrial function genes in post-mortem brain of ASD subjects,11 
suggesting that a mitochondrial dysfunction might enhance the clin-
ical outcome of NRXN1 deletions.
2  | E XPERIMENTAL SEC TION
2.1 | Participants
A total of 89 Italian families with one or more children with an ASD 
diagnosis were recruited at the UOSI Disturbi dello Spettro Autistico, 
IRCCS Istituto delle Scienze Neurologiche (Bologna, Italy).
Assessment and a deep phenotypic characterization of pro-
bands were done using a set of standardized clinical tests to 
evaluate the presence and severity of ASD (ADOS, CARS and 
M-CHAT), to assess both developmental/cognitive levels (PEP-
3, Leiter-R, Griffith Scales, or Wechsler Scales) and adaptive 
behaviour (Vineland Adaptive Behavior Scale, VABS) as well as 
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discrete and clinical signs like mimicry, hyperactivity, sensory ab-
normalities and symptoms onset. Moreover, probands underwent 
EEG and MRI. Subclinical features in relatives were assessed using 
the Social and Communication Disorders Checklist and The Broad 
Autism Phenotype Questionnaire.
The ASD sample includes 78 males and 26 females, from 18 mul-
tiplex and 71 simplex families. DNA samples from both proband's 
parents were available for 87 families, and from a single parent for 
the remaining ones. All DNA samples were extracted from whole 
blood.
All participants provided a written informed consent to par-
ticipate to this study. This study was approved by the local Ethical 
Committee (Comitato Etico di Area Vasta Emilia Centro (CE-AVEC); 
code CE 14060). All research was performed in accordance with the 
relevant guidelines and regulations.
2.2 | Copy number variant analysis
Array-based comparative genomic hybridization (aCGH) was per-
formed on 104 ASD individuals (89 probands, 13 siblings, 1 cousin 
and one uncle) and 5 siblings with another neurodevepmental dis-
orders, using the SurePrint G3 Unrestricted CGH ISCA v2, 8x60K 
(Agilent Technologies) or the SurePrint G3 Human CGH Microarray 
8x60K (Agilent Technologies), following manufacturer's instruc-
tions. Scan images were analysed through the Agilent CytoGenomics 
5.0.1.6 software and aberrations were called by the ADM1 algorithm 
with a threshold of 6.0 and at least three consecutive oligonucleo-
tides with similar log2 ratios.
All CNVs were compared to those collected in different public 
databases: Database of Genomic Variants (DGV, http://proje cts.
tcag.ca/varia tion/), DECIPHER (https://decip her.sanger.ac.uk/), 
ClinVar (https://www.ncbi.nlm.nih.gov/clinv ar/), and database of 
human CNVs hosted by IRCCS OASI Maria SS. (Troina, Italy). The 
American College of Medical Genetics (ACMG) guidelines were used 
for CNV interpretation and reporting.12 According to these criteria, 
the only identified pathogenic CNV is a deletion involving the NRXN1 
gene in a girl with ASD from a simplex family. Parental inheritance 
and validation of NRXN1 deletion were carried out with quantitative 
PCR (qPCR) using SsoAdvanced™ Universal SYBR® Green Supermix 
(BIORAD). The assay was performed in triplicate, with four sets of 
primers corresponding to the region of interest and another mapping 
to a control region on FOXP2 gene at 7q31.1. The number of copies 
of each amplified fragment was calculated using the ddCt method.
2.3 | Whole-exome analysis
DNA from ASD proband and parents was subjected to exome 
capture using NimbleGen SeqCap EZ MedExome enrichment kit 
(Roche), followed by paired-end reads sequencing on an Illumina 
NextSeq550 (Illumina Inc, San Diego, CA, USA). Exomes had a read 
depth (DP) of 10× or more for 90% of the total exome coverage and 
20x or more for 80%. Coverage statistics and comparison of cover-
age between samples was performed using QualiMap,13 showing a 
mean coverage depth of 120-122X for the three samples and a mean 
quality mapping is 58. Data analysis was performed using CoVaCS,14 
a pipeline exploiting a consensus call-set approach from three dif-
ferent algorithms (GATK, Varscan and Freebayes) to generate a 
final set of high-confidence variants. All variants were annotated 
with ANNOVAR, using RefSeq for gene-based annotation (posi-
tion, nomenclature, gene name, gene function). In order to remove 
low-quality variants, genotypes were required to have DP ≥ 10, and 
Genome Quality (GQ) ≥20. A minor allele frequency (MAF) threshold 
of ≤0.5% in gnomAD exome (https://gnomad.broad insti tute.org/)15 
(and <1% in gnomAD genome and the 1000 Genomes Project16) was 
chosen. We selected exonic and splicing variants, excluding synony-
mous variants. Likely deleterious variants were prioritized to capture 
Likely Gene Disrupting (LGD) and damaging missense mutations. 
LGD mutations include stop-gain, stop-loss, frameshift and splicing 
mutations, while missense mutations were defined damaging if they 
satisfy at least two of the following criteria: SIFT ≤ 0.05, Polyphen2 
(HDIV) ≥ 0.95, Mutation Assessor score ≥ 2, CADD ≥ 15, placen-
tal mammal PhyloP ≥ 2.4 and vertebrate PhyloP ≥ 4.17 Mutation 
intolerant genes were defined by two metrics: residual variance to 
intolerance score (RVIS ≤ 20th percentile)18 and probability of loss-
of-function intolerance (pLI score ≥ 0.9).19 To select genes previously 
associated with ASD, we used the SFARI gene database and its scor-
ing system, including 4 categories: S (syndromic), 1 (high confidence), 
2 (strong candidate) and 3 (suggestive evidence) (https://gene.sfari.
org/, Release: 2019 Q4). Brain expressed, synaptic and postsynap-
tic density (PSD) genes were defined as previously described.20-22 
Likely damaging de novo variants have been validated by Sanger se-
quencing method.
2.4 | Deep sequencing of mitochondrial genome
Direct sequence analysis of the entire mtDNA molecule was per-
formed on total DNA extracted from blood, by next generation 
sequencing (NGS) approach.23 Briefly, the mitochondrial genome 
was amplified in two long-range PCR, the NGS library constructed 
by Nextera XT (Illumina) and paired-end sequenced on NextSeq 
Instrument (Illumina), using an High Output Kit (300 cycle). Fastq 
files were analysed with an in-house pipeline, integrating three 
different callers (MToolBox, Unified Genotyper of GATK and 
DetermineVariants)24-26 to detect low-level heteroplasmy.
2.5 | Mitochondrial DNA quantification
MtDNA content was assessed on total DNA extracted from blood, 
using a multiplex probe-based real-time PCR method,27 co-amplify-
ing a mitochondrial gene (MT-ND2) and a nuclear gene (FASLG). All 
three individuals were compared with age-matched control groups 
of healthy individuals.
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3  | RESULTS
3.1 | Comparative genomic hybridization array CGH
Comparative genomic hybridization array CGH was performed in 
104 individuals with ASD.
The only pathogenic CNV identified was a deletion of ~811 kb 
at 2p16.3 (NC_000002.11:g.50170766_50982172del) (Figure 1A) 
involving exons from 7 to 23 of the NRXN1 gene (NM_001135659.2) 
in a trio family. qPCR in all family members confirmed the presence 
of the NRXN1 intragenic deletion in the proband and showed that 
the CNV is inherited from the unaffected mother (Figure S1). We 
identified three other rare CNVs in this family (Table S1), but none of 
them is considered to be clinically relevant.
3.2 | Clinical characterization of the family with the 
NRXN1 deletion
No familiarity for ASD, congenital malformations or intellectual dis-
ability was reported. The female proband was born without pre-, 
peri- or post-natal relevant findings. Birth weight was 3690 kg. 
Development of socio-communicative and motor abilities was re-
ported to be slightly delayed until 18 months of age with acquisition 
of some words. At 18-19 months of age, parents reported a regres-
sion of the acquired socio-communicative abilities: the girl stopped 
responding to simple commands and to her name. Eye-contact was 
lacking, while social isolation started to be more evident. Imitation 
skills, communicative gestures and language stopped. She started 
to show hyperactivity, short attention span and motor stereotypies 
such as hand flapping when excited. She manifested sensory inter-
ests manipulating materials mostly to get visual, acoustic and tactile 
stimulation (ie passing a hair or thread upon her lips, thread waving 
and ripping paper in thin stripes) and a restricted interest for hair 
and threads. At 4.6 years old, language expression was limited to 4 
single words, while language comprehension seemed to be relatively 
better. Hyperactivity appeared to be slightly reduced. No epileptic 
seizures were reported. Diagnosis of ASD was made at 35 months 
old through clinical observation, the Childhood Autism Rating Scale-
Second edition (CARS2-ST)28 and the Autism Diagnostic Observation 
Schedule (ADOS-2: module 1)29 (Table 1). Both diagnostic tests indi-
cated the presence of severe clinical signs of autism. No cognitive or 
psychomotor development level could be assessed using standard-
ized scales due to the lack of the child's compliance. At 4.8 years 
of age, the assessment of adaptive behaviour (Vineland Adaptive 
Behavior Scale)30 showed a significant delay in Communication, 
Daily Living Skills, Socialization and Motor Skills domains (age equiv-
alent = 1.6 years old). Neurological examination showed: macrocra-
nia, speech delay, aloneness, stereotypies as turning around herself, 
and no neuromotor signs. The proband underwent an awake and 
sleep EEG at the age of 2.8 years old, showing only an unspecific 
predominance of a slow background activity in the right temporal 
regions. Parents did not provide consent to perform a brain MRI.
Both parents were evaluated for the presence of subclini-
cal neurocognitive or neuropsychiatric features. Scores for the 
broad autism phenotype were in the normal range (Social and 
Communication Disorders Checklist and The Broad Autism 
Phenotype Questionnaire31,32). To contextualize their phenotypic 
profiles beyond questionnaires, we also investigated their education 
status: they both reached a good education level (high school di-
ploma and bachelor's degree, respectively) with no need for special 
education or services. No family history of psychiatric disorders was 
present, except for the paternal grandfather who was reported to 
take depression medication.
3.3 | Whole-exome sequencing
A trio-based whole-exome sequencing (WES) approach was un-
dertaken for this family. We focused our analysis on rare variants 
(MAF ≤ 0.5%), and more specifically on those predicted to have a 
functional effect, including LGD variants and missense variants 
defined damaging, according to a combination of prediction al-
gorithms.17 We compared the load of rare variants between the 
proband and her mother: the proband has a higher number of rare 
variants compared with the NRXN1 deletion-transmitting mother 
(1036 versus 573). This difference remains significant by considering 
the putative damaging variants only (303 in the proband vs 212 in 
the mother, χ2 = 16.08, P = 6.07 × 10−5). We then tested for trans-
mission disequilibrium of damaging variants from the parents to the 
proband and we detected a preferential transmission of damaging 
variants from the father (203 transmitted vs 165 untransmitted vari-
ants, TDT P = 0.048) but not from the mother.
Genes with at least one LGD or putative damaging missense 
variant or CNV were analysed using the STRING database33 to test 
the presence of an enrichment for functionally related networks of 
genes (Figure 2). This analysis identified a significant 1.2-fold enrich-
ment (223 edges vs 184 expected) in interactions among the 294 
genes identified in the proband (P = 0.003, one-tailed hypergeomet-
ric test), while no significant interaction enrichment was identified 
in NRXN1 deletion-transmitting unaffected mother (84 edges vs 86 
expected, P = 0.62).
Next, we looked for specific sequence variants identified in the 
proband that might contribute to the clinical manifestation of the 
NRXN1 deletion in the affected girl compared with the unaffected 
carrier mother. We first tested the possible presence of compound 
heterozygosity in NRXN1, but we found no rare functional nucle-
otide variants on the non-deleted allele. Then, we focused on four 
categories of rare variants: (a) likely damaging de novo variants, (b) 
recessive-acting variants (homozygous and compound heterozy-
gous variants), (c) likely deleterious variants in genes previously 
implicated in ASD (SFARI genes) that are intolerant to functional 
variation (RVIS ≤ 20th percentile and/or pLI score ≥ 0.9) and (d) 
likely deleterious variants in genes with a predicted interaction with 
NRXN1 in STRING. We identified one de novo stop-gain in CDC25C 
(NP_073720.1:p.(Ser143Xaa)) and de novo missense in WASHC5 
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(NP_001317538.1:p.(Asp254Gly)), 2 homozygous missense variants 
in ZFP37 and DCLRE1A and two compound heterozygous variants in 
IFT80, and 5 missense variants in SFARI ASD candidate genes intol-
erant to mutation (CNTNAP5, ERBIN, SYNE, HERC2 and TANC2); all of 
them, except for TANC2, were of paternal origin in brain expressed 
genes. Furthermore, we highlighted 4 genes with damaging missense 
variants that are predicted to interact with NRXN1 (CNTNAP5, TULP1, 
NCAN and KIRREL2) (Table 2). Among them, the missense variant in 
CNTNAP5 is likely to exert a significant role, given that CNTNAP5 is it-
self a previously known ASD candidate gene, likely to be intolerant to 
mutations (RVIS percentile = 8.4) (Figure 2). Finally, we investigated 
the mother's burden of rare variants in these risk categories and, al-
though we are not able to identify de novo and compound heterozy-
gous variants, there is still a higher number of variants in the proband 
compared with the mother (11 vs 6 variants) (Table S2).
3.4 | Mitochondrial DNA analyses
We carried out deep sequencing of the entire mtDNA in the ASD 
proband and her parents (Table S3 and S4). Both the proband and 
her mother showed all defining variants of haplogroup H13a1a1 of 
European ancestry, whereas the father's variants identified the hap-
logroup L2c2b1b background of African ancestry. None of the rare 
variants were previously reported (private or unique to an individual) 
or predicted as pathogenic.
Taking advantage of the high mean coverage in sequencing 
(16721X in the proband, 12090X in the mother and 19027X in the 
father), we were able to detect variants with a low-level heteroplasmy 
(between 0.2% and 15%), in all three individuals (Table S3 and S4). 
Two of these were present in the proband and inherited from the 
mother: the synonymous variant NC_012920.1(MT-ND2):m.4847C>T 
and the non-coding NC_012920.1(MT-HV1):m.16092T>C , one of 
the hypervariable domains of the control region. The heteroplasmy 
of these variants was higher in the proband (13.6% and 12.7%, re-
spectively) as compared with the mother (2.2% and 2.1%, respec-
tively). Furthermore, other five variants with a very low-level of 
heteroplasmy (0.2%-0.7%) were found exclusively in the proband: 
the NC_012920.1(MT-RNR2):m.1906G>A, NC_012920.1(MT-
RNR2):m.2009G>A and NC_012920.1(MT-TL1):m.3242G>A, 
which were never reported in over 50.000 sequence (GenBank), 
whereas the missense NC_012920.1(MT-CO3):p.(Val208Ile) and 
F I G U R E  1   NRXN1 deletion in the ASD proband. A, UCSC hg19 screenshot showing the NRXN1 maternally inherited deletion detected 
by array CGH in the female proband and validated by qPCR in the family. qPCR probes used for validation and inheritance testing are shown 
in green. B, Schematic representation outlining domains structure of neurexin alpha and neurexin beta protein variants. Canonical splice 
sites (SS) of neurexins are indicated by arrows. Protein region affected by deletion is highlighted in red [Colour figure can be viewed at 
wileyonlinelibrary.com]
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the non-coding NC_012920.1(MT-HV1):m.16348C>T variants were 
previously reported three and six times, respectively. The missense 
NC_012920.1(MT-CO3):p.(Val208Ile) variant, even if never reported 
as pathogenic for any disease, was predicted to be deleterious. The 
mother presented only one private low-level heteroplasmic variant, 
the missense NC_012920.1(MT-ND5):p.(Phe326Ser,) (2.2%), never 
reported in GenBank and also predicted to be deleterious. The fa-
ther presented four low-level heteroplasmic variants: the missense 
NC_012920.1(MT-CYB):p.(Gly251Asp) (0.6%), reported 6 time in 
GenBank and predicted to be deleterious, and the non-coding vari-
ants NC_012920.1(MT-HV1):m.16192C>T (0.4%), NC_012920.1(MT-
HV1):m.16256C>T (0.8%), NC_012920.1(MT-HV1):m.16291C>T 
(0.9%), very frequent in GenBank (2029, 1645, 1341, respectively).
To verify the remote possibility of biparental inheritance, as 
recently reported,34 we also compared the proband and her father 
mtDNA sequences. With the exception of the reference sequence 
private variants,35 the proband and her father did no share any 
other variants, not even at low-level heteroplasmy (Table S3 and 
S4).
Last, the mtDNA content of the proband and her parents 
was comparable to the range of age-matched healthy individuals 
(Figure S2).
4  | DISCUSSION
In this study, we identified an intragenic NRXN1 deletion in a female 
proband with ASD, who has inherited it from the unaffected mother. 
We have thus characterized rare variants in the nuclear and mito-
chondrial genome of this family, in order to investigate their contri-
bution towards the manifestation of the ASD phenotype in NRXN1 
deletion carriers.
The NRXN1 deletion identified in this family can be classified as 
a 3’deletion,8 as it overlaps exons from 7 to 23 (NM_001135659.2). 
TA B L E  1   Summary of clinical data
Mother Father Proband
Age at first assessment NA NA 23 mo
Sex F M F
Microarray NRXN1 del/+ NRXN1 +/+ NRXN1 del/+
Morphology
Growth at birth NA NA Weight = 3.69 kg (50%ile); length = 56 cm 
(85%-97%ile)
Head circumference (%ile) NA NA Birth = 38.2 cm (>98%ile); 31 mo = 53 cm 
(>98%ile); 60 mo = 54.5 cm (>98°perc.)
Neurodevelopment
Full-scale IQ NA NA NA-NC
Speech delay - - +
Adaptive level of 
functioning*
NA NA Vineland Adaptive Behavior Scales: CA: 
4.8 y; Global AE: 1.6 y
Clinical diagnosis NA NA Autism spectrum disorder
Autism scales
CARS2-ST NA NA Total score = 46 (severe autistic 
symptoms) Autism cut- off: 30
ADOS-2 (module 1) NA NA Total score = over Autism cut-off, 
Comparison score = 10 (severe autism)
Broad autism phenotype
Broad Autism Phenotype 
Questionnaire (BAPQ)
Within normal range, Scores 
under cut-off for Aloof , Rigid, 
and Pragmatic language
Within normal range, Scores 
under cut-off for Aloof , Rigid, 
and Pragmatic language
NA
Social and Communication 
Disorder Checklist (SCDC)
T = 4 (<cut-off: 9) T = 2 (<cut-off:9) NA
Neurological
EEG NA NA Aspecific abnormalities: slow activity in 
right temporal regions
Congenital
Other medical - stuttering -
Abbreviations: ±, positive/negative for attribute; AE, age equivalent; CA, chronological age; NA, information not available; NC, non-collaborative 
patient.
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F I G U R E  2   STRING network of predicted protein-protein interactions for genes harbouring LGD or likely damaging missense variants 
identified by WES in the female proband. The network of predicted NRXN1 associations has been magnified. The edges represent the 
predicted functional associations and line colour indicates the type of interaction evidence: Red line—presence of fusion evidence; Green 
line—neighbourhood evidence; Blue line—cooccurrence evidence; Purple line—experimental evidence; Yellow line—text-mining evidence; 
Light blue line—database evidence; Black line—co-expression evidence. NRXN1 and CNTNAP5 show homology, co-expression and text-
mining interaction evidence; NRXN1 and KIRREL2 show text-mining interaction evidence; NRXN1 and NCAN show co-expression and text-
mining interaction evidence; NRXN1 and TULP1 show co-expression and experimental interaction evidence [Colour figure can be viewed at 
wileyonlinelibrary.com]
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The deletion gives rise to a putative in-frame transcript, lacking 
the majority of NRXN1 protein domains (from Gly311 to Leu1445), 
specifically all α-neurexin LNS-domains (laminin/neurexin/sex hor-
mone-binding globulin domains) except the first one, and the two 
intercalated epidermal growth factor (EGF)-like domains, while 
maintaining the transmembrane and intracellular C-terminal domain 
(Figure 1B). Moreover, the deletion impacts the canonical splice sites 
(SS2 to SS6), including SS4, thought to represent a key mechanism 
for the regulation of NRXN-ligand interactions at synapses.9 As the 
3’deletion identified in our proband is in-frame, it is possible that 
the phenotypic effect of this deletion may arise by two concurrent 
mechanisms: haploinsufficiency due to lack of wild-type NRXN1α 
isoforms, and a dominant-negative activity of the mutant splice iso-
form, as suggested by a recent study using induced pluripotent stem 
cell (hiPSC)-derived neurons from subjects with heterozygous intra-
genic deletions.36
The proband's phenotype is mainly compatible with clinical fea-
tures of 3’ deletion carriers, as the girl with ASD has macrocephaly 
(10.3% of 3’deletion carriers had macrocephaly in comparison with 
only 1.2% of 5’ deletion carriers) and DD (more frequently presents 
in probands with 3’ deletions).8 Given the importance of collecting 
phenotype information also on parents to look for possible endophe-
notypes, we have also evaluated both parents for the presence of 
broad autism phenotype signs, but scores in questionnaires (SCDC, 
BAPQ) were not consistent with any ASD traits in either of them.
Whole-exome sequencing analysis in all family members iden-
tified a higher number of rare coding variants in the ASD child in 
comparison with the NRXN1 deletion-transmitting mother and this 
difference remains statistically significant if we restrict the analy-
sis to rare likely deleterious mutations only, suggesting that addi-
tional rare variants may contribute collectively to push the genetic 
liability beyond the threshold for ASD. Moreover, a significant in-
teraction enrichment was detected among genes with damaging 
variants (CNVs and SNVs) in the proband, supporting a cumulative 
effect of interacting genes affected by mutations to the phenotype. 
Interestingly, among the NRXN1 interactions detected by STRING in 
the ASD proband, there is a predicted interaction with CNTNAP5, a 
functionally intolerant gene previously identified as an ASD candi-
date gene, which harbours a paternally inherited putative damaging 
missense variant. CNTNAP5 encodes for contactin-associated pro-
tein-like 5, a member of the neurexin family involved in cell adhesion 
and intercellular communication in the vertebrate nervous system.37 
CNTNAP5 is classified as a suggestive candidate gene for ASD (SFARI 
score 3), as a rare deletion and missense variants in CNTNAP5 have 
been identified in subjects with ASD.38 Similarly to this report, a 
previous study identified a maternally inherited missense variant in 
CNTNAP5 segregating with a NRXN3 paternal deletion in two ASD 
siblings,39 supporting a combined role of neurexins and contac-
tin-associated proteins in ASD risk.
In addition to CNTNAP5, damaging missense variants were iden-
tified in four other mutation intolerant genes, previously implicated 
in ASD: TANC2, ERBIN, SYNE1 and HERC2.40-50 While TANC2 and 
ERBIN have been involved in idiopathic ASD susceptibility with high 
confidence (SFARI score 1 and 2, respectively), SYNE1 and HERC2 
gene have been mostly involved in syndromic ASD. Moreover, 
TANC2 and ERBIN are interesting functional candidate genes. TANC2 
is highly expressed in the human developing brain and encodes for a 
postsynaptic scaffold protein involved in dendritic spines and excit-
atory synapses regulation.51 ERBIN encodes a postsynaptic protein 
which binds ERBB2 playing an important role during brain develop-
ment and regulation of synaptic plasticity in the adult brain.52 ERBIN 
is also implicated in dendritic morphogenesis by regulating localiza-
tion and function of δ-Catenin in hippocampal neurons.53
Two de novo novel putative damaging variants were also iden-
tified in the proband: a stop-gain variant located on CDC25C exon 
5 (NP_073720.1:p.(Ser143Xaa)) and a predicted damaging mis-
sense variant in WASHC5 exon 9 (NP_001317538.1:p.(Asp254Gly)). 
Although neither of them have been previously implicated in ASD, 
both of them are expressed in the brain22 and therefore they could 
contribute to the proband phenotype. It should be noted that 
heterozygous missense variants in WASHC5 are associated with 
autosomal dominant spastic paraplegia 8 (SPG8), a progressive up-
per-motor neurodegenerative disease,54 while biallelic pathogenic 
variants are also associated with Ritscher-Schinzel Syndrome, a clin-
ically recognizable condition characterized by distinctive craniofa-
cial features, cerebellar defects and cardiovascular malformations.55 
The WASHC5 variant (NP_001317538.1:p.(Asp254Gly)) is predicted 
to be deleterious, is novel and it is located in the spectrin-like re-
peat domain, thus, we cannot rule out a pathological role for this 
mutation for a spastic paraplegia phenotype, which usually has on 
onset in adult life. Moreover, although the proband did not show 
typical dysmorphic craniofacial features of individuals with Ritscher-
Schinzel, she presented macrocrania.
Recessive-acting variants were identified in three genes (ZFP37, 
DCLRE1A and IFT80), all of which are brain-expressed22 but neither 
of them have been previously implicated in neurodevelopmental 
phenotypes.
Finally, the proband did not carry any pathogenic mutation in 
her mtDNA. However, we found five variants with low-level hetero-
plasmy (ranging from 0.2% to 0.7%) that were absent in the mother, 
and two maternally inherited variants, which increased their hetero-
plasmic load in the proband as compared to the mother. The burden 
of low-level heteroplasmic mtDNA variants, both inherited or de 
novo, also known as universal heteroplasmy,56 might contribute to 
the risk of developing ASD, but further analyses on large cohorts are 
needed to validate this hypothesis. The mtDNA copy number was 
also uninformative.
In conclusion, we have characterized a trio family in which a 
large 3’ exonic NRXN1 deletion is transmitted from an unaffected 
mother to a child with ASD. Exonic NRXN1 deletions represent 
the prototype of incomplete penetrant ASD-associated suscep-
tibility variants as they are often inherited from unaffected or 
mildly affected parents, but they are still considered pathogenic. 
The key finding is the presence of an increased burden of exonic 
rare variants in the affected proband compared to the unaffected 
deletion-transmitting mother, supporting the hypothesis that the 
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NRXN1 deletion sensitizes the genome to a clinical manifestation, 
but other genetic contributors are necessary to cross the threshold 
for a phenotypic manifestation (Figure 3).57 Moreover, the reduced 
penetrance of the NRXN1 deletion in the unaffected mother is con-
sistent with a female protective effect: females would require an 
excess burden of deleterious CNVs and SNVs to reach the ASD 
diagnostic threshold.58 Therefore, in this family, the paternal-in-
herited rare variants in ASD-related or functionally constrained 
genes and de novo rare variants identified in the proband may 
have additive effects acting on a sensitized background caused 
by haploinsufficiency and/or a dominant-negative activity at the 
NRXN1 locus. This observation is in line with the hypothesis that 
the determinants of psychiatric traits are multifactorial even in the 
context of a large-effect variant. These modifying determinants 
may include the genetic background of common polygenic vari-
ants as well as rare variants. It has been recently reported that the 
increased burden of rare likely deleterious variants enhances the 
expression of neurodevelopmental phenotypes in probands with 
16p21.1 deletions and in probands with other gene disruptive vari-
ants compared with their carrier family members59; hence, in this 
study, we have focused our attention on the background of rare 
variants. Our results are consistent with the hypothesis that the 
burden of rare variants contributes in defining the phenotypic tra-
jectory in carriers of a large-effect variant, thus, this may represent 
a widespread mechanism that modulates the penetrance and the 
expressivity of disease-associated variants. However, it has been 
shown that also common polygenic variation contributes additively 
to ASD risk, even in cases that carry a strongly acting variant.60,61 
A limitation to our study is therefore that we were not able to test 
the potential contribution of common variation in modulating the 
penetrance of the NRXN1 deletion in this family.
Further investigation in a large dataset will be necessary to prop-
erly evaluate the cumulative effects of rare deleterious and com-
mon variants to ASD risk in NRXN1 deletion carriers; family-based 
samples will be particularly informative, as they allow intrafamilial 
comparison of phenotypic features and inheritance pattern of spe-
cific variants.
This study underlines the importance of a comprehensive as-
sessment of the genomic landscape of ASD individuals even when 
a ‘likely pathogenic’ variant has been already identified, as it is ap-
parent that multiple rare variants contribute in conjunction to the 
overall genetic risk and the final clinical outcome. It is time to move 
from a genetic to a genomic perspective, shifting from a single vari-
ant analysis to an integrated view of many variants of different origin 
(nuclear and mitochondrial), types (CNVs and SNVs), inheritance pat-
tern (de novo and inherited), frequency (rare and common, hetero-
plasmic and homoplasmic) and effect sizes, considering the role of 
protein-protein interactions.
ACKNOWLEDG MENTS
We gratefully acknowledge all the subjects who have participated 
in the study. We thank the Centro Interdipartimentale di Ricerche 
F I G U R E  3   Multi-factorial threshold 
model for ASD in this family. Each family 
member has an ASD risk cup with balls 
representing risk variants that contribute 
to ASD with variable degrees of impact. In 
both parents, the burden of risk variants is 
not enough to develop ASD, while in the 
child the ASD threshold is reached as a 
combination of strong and weak, inherited 
and de novo genetic variants. The NRXN1 
deletion is depicted as a strong, primary 
contributing factor to reaching the ASD 
threshold in the ASD child, but not 
sufficient alone to develop ASD in the 
deletion carrier mother57 [Colour figure 
can be viewed at wileyonlinelibrary.com]
     |  2469CAMELI Et AL.
sul Cancro ‘Giorgio Prodi' (CIRC), University of Bologna for Illumina 
Sequencing Service and CINECA for computational resources.
CONFLIC T OF INTERE S T
The authors confirm that there are no conflicts of interest.
AUTHOR CONTRIBUTIONS
Cinzia Cameli: Data curation (equal); Formal analysis (equal); 
Investigation (equal); Software (equal); Validation (lead); 
Visualization (equal); Writing-original draft (supporting). Marta 
Viaggiano: Data curation (equal); Formal analysis (equal); 
Investigation (equal); Software (equal); Validation (supporting); 
Visualization (equal). Magali Jane Rochat: Formal analysis (equal); 
Funding acquisition (equal); Investigation (equal); Resources (sup-
porting); Visualization (equal); Writing-original draft (supporting). 
Alessandra Maresca: Formal analysis (equal); Funding acquisition 
(equal); Investigation (equal); Writing-original draft (supporting). 
Leonardo Caporali: Formal analysis (equal); Investigation (equal); 
Writing-original draft (supporting). Claudio Fiorini: Formal analysis 
(equal); Investigation (equal); Writing-original draft (supporting). 
Flavia Palombo: Investigation (equal); Software (equal). Pamela 
Magini: Investigation (equal). Renée Concetta Duardo: Investigation 
(equal). Fabiola Ceroni: Validation (supporting). Maria Cristina 
Scaduto: Investigation (equal); Resources (supporting). Annio 
Posar: Investigation (equal); Resources (supporting). Marco Seri: 
Supervision (equal). Valerio Carelli: Methodology (equal); Project 
administration (equal); Supervision (equal); Writing-review & editing 
(equal). Paola Visconti: Methodology (equal); Project administra-
tion (equal); Resources (lead); Supervision (equal); Writing-review 
& editing (equal). ELENA BACCHELLI: Conceptualization (equal); 
Formal analysis (equal); Funding acquisition (equal); Methodology 
(equal); Project administration (equal); Software (equal); Supervision 
(equal); Visualization (equal); Writing-original draft (lead); Writing-
review & editing (equal). Elena Maestrini: Conceptualization (equal); 
Methodology (equal); Project administration (equal); Supervision 
(equal); Writing-review & editing (equal).
DATA AVAIL ABILIT Y S TATEMENT
The data that support the findings of this study are available in the 
supplementary material of this article.
ORCID
Elena Bacchelli  https://orcid.org/0000-0001-8800-9568 
R E FE R E N C E S
 1. Maenner MJ, Shaw KA, Baio J, et al. Prevalence of autism spectrum 
disorder among children aged 8 years - autism and developmen-
tal disabilities monitoring network, 11 sites, United States, 2016. 
MMWR Surveill Summ. 2020;69(4):1-12.
 2. Sullivan PF, Geschwind DH. Defining the genetic, genomic, cel-
lular, and diagnostic architectures of psychiatric disorders. Cell. 
2019;177(1):162-183.
 3. Pinto D, Delaby E, Merico D, et al. Convergence of genes and cellu-
lar pathways dysregulated in autism spectrum disorders. Am J Hum 
Genet. 2014;94(5):677-694.
 4. Coe BP, Stessman HAF, Sulovari A, et al. Neurodevelopmental dis-
ease genes implicated by de novo mutation and copy number varia-
tion morbidity. Nat Genet. 2019;51(1):106-116.
 5. Satterstrom FK, Kosmicki JA, Wang J, et al. Large-scale exome 
sequencing study implicates both developmental and functional 
changes in the neurobiology of autism. Cell. 2020;180(3):568-584.
e523.
 6. Girirajan S, Rosenfeld JA, Cooper GM, et al. A recurrent 16p12.1 
microdeletion supports a two-hit model for severe developmental 
delay. Nat Genet. 2010;42(3):203-209.
 7. Lowther C, Speevak M, Armour CM, et al. Molecular characteri-
zation of NRXN1 deletions from 19,263 clinical microarray cases 
identifies exons important for neurodevelopmental disease expres-
sion. Genet Med. 2017;19(1):53-61.
 8. Cosemans N, Vandenhove L, Vogels A, et al. The clinical relevance 
of intragenic NRXN1 deletions. J Med Genet. 2020.
 9. Sudhof TC. Synaptic neurexin complexes: a molecular code for the 
logic of neural circuits. Cell. 2017;171(4):745-769.
 10. Pei L, Wallace DC. Mitochondrial etiology of neuropsychiatric dis-
orders. Biol Psychiatry. 2018;83(9):722-730.
 11. Schwede M, Nagpal S, Gandal MJ, et al. Strong correlation of 
downregulated genes related to synaptic transmission and mito-
chondria in post-mortem autism cerebral cortex. J Neurodev Disord. 
2018;10(1):18.
 12. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST. 
American College of Medical Genetics standards and guidelines for 
interpretation and reporting of postnatal constitutional copy num-
ber variants. Genet Med. 2011;13(7):680-685.
 13. Konechnikov K, Conesa A, García-Alcalde F. Qualimap 2: advanced 
multi-sample quality control for high-throughput sequencing data. 
Bioinformatics (Oxford, England). 2016;32(2):292-294.
 14. Chiara M, Gioiosa S, Chillemi G, et al. CoVaCS: a consensus variant 
calling system. BMC Genom. 2018;19(1):120.
 15. Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 
human exomes and genomes reveals the spectrum of loss-of-
function intolerance across human protein-coding genes. BioRxiv. 
2019;531210
 16. Auton A, Brooks LD, Durbin RM, et al. A global reference for human 
genetic variation. Nature. 2015;526(7571):68-74.
 17. Yuen RKC, Thiruvahindrapuram B, Merico D, et al. Whole-genome 
sequencing of quartet families with autism spectrum disorder. Nat 
Med. 2015;21(2):185-191.
 18. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic in-
tolerance to functional variation and the interpretation of personal 
genomes. PLoS Genet. 2013;9(8):e1003709.
 19. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding ge-
netic variation in 60,706 humans. Nature. 2016;536(7616):285-291.
 20. Bayés À, van de Lagemaat LN, Collins MO, et al. Characterization 
of the proteome, diseases and evolution of the human postsynaptic 
density. Nat Neurosci. 2011;14(1):19-21.
 21. Jansen A, Dieleman GC, Smit AB, et al. Gene-set analysis shows 
association between FMRP targets and autism spectrum disorder. 
Eur J Hum Genet. 2017;25(7):863-868.
 22. Kang HJ, Kawasawa YI, Cheng F, et al. Spatio-temporal transcrip-
tome of the human brain. Nature. 2011;478(7370):483-489.
 23. Caporali L, Iommarini L, La Morgia C, et al. Peculiar combinations of 
individually non-pathogenic missense mitochondrial DNA variants 
cause low penetrance Leber's hereditary optic neuropathy. PLoS 
Genet. 2018;14(2):e1007210.
 24. Calabrese C, Simone D, Diroma MA, et al. MToolBox: a highly au-
tomated pipeline for heteroplasmy annotation and prioritization 
2470  |     CAMELI Et AL.
analysis of human mitochondrial variants in high-throughput se-
quencing. Bioinformatics. 2014;30(21):3115-3117.
 25. DePristo MA, Banks E, Poplin R, et al. A framework for variation 
discovery and genotyping using next-generation DNA sequencing 
data. Nat Genet. 2011;43(5):491-498.
 26. Weissensteiner H, Forer L, Fuchsberger C, et al. mtDNA-Server: 
next-generation sequencing data analysis of human mitochondrial 
DNA in the cloud. Nucleic Acids Res. 2016;44(W1):W64-69.
 27. Giordano C, Iommarini L, Giordano L, et al. Efficient mitochondrial 
biogenesis drives incomplete penetrance in Leber's hereditary optic 
neuropathy. Brain. 2014;137(Pt 2):335-353.
 28. Schopler E, Van Bourgondien ME, Wellman GJ, Love SR. CARS2 
Childhood Autism Rating Scale, 2nd ed. Los Angeles, CA: Western 
Psychological Services; 2010.
 29. Lord C, Rutter M, Dilavore PC, Risi S, Gotham K, Bishop SL. Autism 
Diagnostic Observation Schedule, 2nd ed. Torrance, CA: Western 
Psychological Services; 2012.
 30. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior 
Scales. Circle Pines, MN: American Guidance Service; 1984.
 31. Skuse DH, Mandy WP, Scourfield J. Measuring autistic traits: her-
itability, reliability and validity of the Social and Communication 
Disorders Checklist. Br J Psychiatry. 2005;187:568-572.
 32. Hurley RS, Losh M, Parlier M, Reznick JS, Piven J. The broad autism 
phenotype questionnaire. J Autism Dev Disord. 2007;37(9):1679-1690.
 33. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein 
association networks with increased coverage, supporting func-
tional discovery in genome-wide experimental datasets. Nucleic 
Acids Res. 2019;47(D1):D607-D613.
 34. Luo S, Valencia CA, Zhang J, et al. Biparental inheritance 
of mitochondrial DNA in humans. Proc Natl Acad Sci U S A. 
2018;115(51):13039-13044.
 35. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull 
DM, Howell N. Reanalysis and revision of the Cambridge ref-
erence sequence for human mitochondrial DNA. Nat Genet. 
1999;23(2):147.
 36. Flaherty E, Zhu S, Barretto N, et al. Neuronal impact of patient-specific 
aberrant NRXN1alpha splicing. Nat Genet. 2019;51(12):1679-1690.
 37. Traut W, Weichenhan D, Himmelbauer H, Winking H. New mem-
bers of the neurexin superfamily: multiple rodent homologues of 
the human CASPR5 gene. Mamm Genome. 2006;17(7):723-731.
 38. Pagnamenta AT, Bacchelli E, de Jonge MV, et al. Characterization 
of a family with rare deletions in CNTNAP5 and DOCK4 sug-
gests novel risk loci for autism and dyslexia. Biol Psychiatry. 
2010;68(4):320-328.
 39. Vaags A, Lionel A, Sato D, et al. Rare deletions at the neurexin 3 locus 
in autism spectrum disorder. Am J Hum Genet. 2012;90(1):133-141.
 40. De Rubeis S, He X, Goldberg AP, et al. Synaptic, transcriptional and 
chromatin genes disrupted in autism. Nature. 2014;515(7526):209-215.
 41. Krumm N, Turner TN, Baker C, et al. Excess of rare, inherited trun-
cating mutations in autism. Nat Genet. 2015;47(6):582-588.
 42. Iossifov I, O’Roak BJ, Sanders SJ, et al. The contribution of de 
novo coding mutations to autism spectrum disorder. Nature. 
2014;515(7526):216-221.
 43. Liu Y, Liang Y, Cicek AE, et al. A statistical framework for mapping 
risk genes from de novo mutations in whole-genome-sequencing 
studies. Am J Hum Genet. 2018;102(6):1031-1047.
 44. Guo H, Bettella E, Marcogliese PC, et al. Disruptive mutations in 
TANC2 define a neurodevelopmental syndrome associated with 
psychiatric disorders. Nat Commun. 2019;10(1):4679.
 45. Yu T, Chahrour M, Coulter M, et al. Using whole-exome sequencing 
to identify inherited causes of autism. Neuron. 2013;77(2):259-273.
 46. O’Roak BJ, Vives L, Girirajan S, et al. Sporadic autism exomes re-
veal a highly interconnected protein network of de novo mutations. 
Nature. 2012;485(7397):246-250.
 47. Wu H, Li H, Bai T, et al. Phenotype-to-genotype approach reveals 
head-circumference-associated genes in an autism spectrum disor-
der cohort. Clin Genet. 2020;97(2):338-346.
 48. Li J, Shi M, Ma Z, et al. Integrated systems analysis reveals a molec-
ular network underlying autism spectrum disorders. Mol Syst Biol. 
2014;10:774.
 49. Ruzzo EK, Pérez-Cano L, Jung J-Y, et al. Inherited and de novo ge-
netic risk for autism impacts shared networks. Cell. 2019;178(4):850-
866.e826.
 50. Stessman HAF, Xiong BO, Coe BP, et al. Targeted sequencing iden-
tifies 91 neurodevelopmental-disorder risk genes with autism and 
developmental-disability biases. Nat Genet. 2017;49(4):515-526.
 51. Han S, Nam J, Li Y, et al. Regulation of dendritic spines, spatial mem-
ory, and embryonic development by the TANC family of PSD-95-
interacting proteins. J Neurosci. 2010;30(45):15102-15112.
 52. Huang YZ, Won S, Ali DW, et al. Regulation of neuregulin signal-
ing by PSD-95 interacting with ErbB4 at CNS synapses. Neuron. 
2000;26(2):443-455.
 53. Arikkath J, Israely I, Tao Y, Mei L, Liu X, Reichardt LF. Erbin controls 
dendritic morphogenesis by regulating localization of delta-catenin. 
J Neurosci. 2008;28(28):7047-7056.
 54. Ginanneschi F, D'Amore A, Barghigiani M, Tessa A, Rossi A, 
Santorelli FM. SPG8 mutations in Italian families: clinical data and 
literature review. Neurol Sci. 2020;41(3):699-703.
 55. Elliott AM, Simard LR, Coghlan G, et al. A novel mutation in 
KIAA0196: identification of a gene involved in Ritscher-
Schinzel/3C syndrome in a First Nations cohort. J Med Genet. 
2013;50(12):819-822.
 56. Payne BAI, Wilson IJ, Yu-Wai-Man P, et al. Universal heteroplasmy 
of human mitochondrial DNA. Hum Mol Genet. 2013;22(2):384-390.
 57. Hoang N, Cytrynbaum C, Scherer SW. Communicating complex ge-
nomic information: a counselling approach derived from research 
experience with Autism Spectrum Disorder. Patient Educ Couns. 
2018;101(2):352-361.
 58. Jacquemont S, Coe B, Hersch M, et al. A higher mutational burden 
in females supports a "female protective model" in neurodevelop-
mental disorders. Am J Hum Genet. 2014;94(3):415-425.
 59. Pizzo L, Jensen M, Polyak A, et al. Rare variants in the genetic 
background modulate cognitive and developmental phenotypes 
in individuals carrying disease-associated variants. Genet Med. 
2019;21(4):816-825.
 60. Robinson EB, Samocha KE, Kosmicki JA, et al. Autism spectrum 
disorder severity reflects the average contribution of de novo and 
familial influences. PNAS. 2014;111(42):15161-15165.
 61. Weiner DJ, Wigdor EM, Ripke S, et al. Polygenic transmission 
disequilibrium confirms that common and rare variation act ad-
ditively to create risk for autism spectrum disorders. Nat Gen. 
2017;49(7):978-985.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Cameli C, Viggiano M, Rochat MJ, et 
al. An increased burden of rare exonic variants in NRXN1 
microdeletion carriers is likely to enhance the penetrance for 
autism spectrum disorder. J Cell Mol Med. 2021;25:2459–
2470. https://doi.org/10.1111/jcmm.16161
